Project Lead

Dr Rochelle Sleaby

A headshot of Dr Rochelle Sleaby. She has long black hair and is wearing a blue shirt.

Almost 1.2 million Australians were living with type 2 diabetes in 2021, and this is expected to increase. A growing body of evidence supports the idea that variation exists not only in type 2 diabetes presentation and progression, but also in individual responses to therapy, which suggests that a one-size-fits-all approach to diabetes management is inappropriate and will have an adverse impact on provision of health services, expenditure and health outcomes as the population with diabetes increases. Precision diabetes medicine evolves the existing one-size-fits-all approach, into one in which data enhances clinical decisions at the subgroup, if not at the individual level. I propose to address three research questions which will explore the evidence base for precision medicine for diabetes in primary care (systematic review), stakeholder perspectives on precision medicine and its implementation (semi-structured interviews), and whether digital phenotypes to practice precision medicine exist in primary care data (linked datasets).